Sulforaphane prevents doxorubicin-induced oxidative stress and cell death in rat H9c2 cells

International Journal of Molecular Medicine

Volumn 36, Issue 1, 2015, Pages 53-64

  Li, Bo ^a   Kim, Do Sung ^a   Yadav, Raj Kumar ^a   Kim, Hyung Ryong ^b   Chae, Han Jung ^a  

^a Chonbuk National University   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

Cardiotoxicity; Doxorubicin; Heme oxygenase 1; NF E2 related factor 2; Reactive oxygen species; Sulforaphane

Indexed keywords

CASPASE 3; CYTOCHROME C; DOXORUBICIN; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MESSENGER RNA; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BAX PROTEIN, RAT; CARDIOTONIC AGENT; ISOTHIOCYANIC ACID DERIVATIVE; KEAP1 PROTEIN, RAT; NFE2L2 PROTEIN, RAT; SIGNAL PEPTIDE; SULFORAFAN;

ANIMAL CELL; ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL COUNT; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME INDUCTION; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; MITOCHONDRIAL MEMBRANE POTENTIAL; MYOBLAST; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRYPAN BLUE ASSAY; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARDIOTONIC AGENTS; CASPASE 3; CELL LINE; CYTOCHROMES C; DOXORUBICIN; ENZYME ACTIVATION; HEME OXYGENASE-1; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOTHIOCYANATES; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; MEMBRANE POTENTIAL, MITOCHONDRIAL; MYOBLASTS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER;

EID: 84930333198     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2199     Document Type: Article

References (61)

1. Vilaseca J, Guardia J, Bacardi R and Monné J: Doxorubicin for liver cancer. Lancet 1: 1367, 1978.
2. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C and Spalla C: Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 11: 1101-1110, 1969.
3. Hortobágyi GN: Anthracyclines in the treatment of cancer. An overview. Drugs 54 (Suppl 4): S1-S7, 1997.
4. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741, 1999.
5. Muggia FM: Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 54 (Suppl 4): S22-S29, 1997.
6. Naito S, Kotoh S, Omoto T, Osada Y, Sagiyama K, Iguchi A, Ariyoshi A, Hiratsuka Y and Kumazawa J; The Kyushu University Urological Oncology Group: Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: A randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. Cancer Chemother Pharmacol 42: 367-372, 1998.
7. Mukhopadhyay P, Rajesh M, Bátkai S, Kashiwaya Y, Haskó G, Liaudet L, Szabó C and Pacher P: Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 296: H1466-H1483, 2009.
8. Childs AC, Phaneuf SL, Dirks AJ, Phillips T and Leeuwenburgh C: Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 62: 4592-4598, 2002.
9. Tatlidede E, Sehirli O, Velioʇlu-Oʇünc A, Cetinel S, Yeʇen BC, Yarat A, Süleymanoʇlu S and Sener G: Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res 43: 195-205, 2009.
10. Wang XL, Wang X, Xiong LL, Zhu Y, Chen HL, Chen JX, Wang XX, Li RL, Guo ZY, Li P and Jiang W: Salidroside improves doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis. J Cardiovasc Pharmacol 62: 512-523, 2013.
11. Kim DS, Woo ER, Chae SW, Ha KC, Lee GH, Hong ST, Kwon DY, Kim MS, Jung YK, Kim HM, et al: Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-kappaB activation. Life Sci 80: 314-323, 2007.
12. Zhang Y, Talalay P, Cho CG and Posner GH: A major inducer of anticarcinogenic protective enzymes from broccoli: Isolation and elucidation of structure. Proc Natl Acad Sci USA 89: 2399-2403, 1992.
13. Sakao K and Singh SV: D,L-sulforaphane-induced apoptosis in human breast cancer cells is regulated by the adapter protein p66Shc. J Cell Biochem 113: 599-610, 2012.
14. Nestle M: Broccoli sprouts as inducers of carcinogen-detoxifying enzyme systems: Clinical, dietary, and policy implications. Proc Natl Acad Sci USA 94: 11149-11151, 1997.
15. Tanito M, Masutani H, Kim YC, Nishikawa M, Ohira A and Yodoi J: Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice. Invest Ophthalmol Vis Sci 46: 979-987, 2005.
16. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
17. Yoon HY, Kang NI, Lee HK, Jang KY, Park JW and Park BH: Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem Pharmacol 75: 2214-2223, 2008.
18. Zhao J, Kobori N, Aronowski J and Dash PK: Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci Lett 393: 108-112, 2006.
19. Satoh T, Okamoto SI, Cui J, Watanabe Y, Furuta K, Suzuki M, Tohyama K and Lipton SA: Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. Proc Natl Acad Sci USA 103: 768-773, 2006.
20. Barbagallo I, Galvano F, Frigiola A, Cappello F, Riccioni G, Murabito P, D'Orazio N, Torella M, Gazzolo D and Li Volti G: Potential therapeutic effects of natural heme oxygenase-1 inducers in cardiovascular diseases. Antioxid Redox Signal 18: 507-521, 2013.
21. Jazwa A and Cuadrado A: Targeting heme oxygenase-1 for neuroprotection and neuroinflammation in neurodegenerative diseases. Curr Drug Targets 11: 1517-1531, 2010.
22. Wang RQ, Nan YM, Wu WJ, Kong LB, Han F, Zhao SX, Kong L and Yu J: Induction of heme oxygenase-1 protects against nutritional fibrosing steatohepatitis in mice. Lipids Health Dis 10: 31, 2011.
23. Angeloni C, Leoncini E, Malaguti M, Angelini S, Hrelia P and Hrelia S: Modulation of phase II enzymes by sulforaphane: Implications for its cardioprotective potential. J Agric Food Chem 57: 5615-5622, 2009.
24. Piao CS, Gao S, Lee GH, Kim S, Park BH, Chae SW, Chae HJ and Kim SH: Sulforaphane protects ischemic injury of hearts through antioxidant pathway and mitochondrial K(ATP) channels. Pharmacol Res 61: 342-348, 2010.
25. Strober W: Trypan blue exclusion test of cell viability. Curr Protoc Immunol Appendix 3: Appendix 3B, 2001.
26. Latt SA and Wohlleb JC: Optical studies of the interaction of 33258 Hoechst with DNA, chromatin, and metaphase chromosomes. Chromosoma 52: 297-316, 1975.
27. Chae HJ, Kim HR, Xu C, Bailly-Maitre B, Krajewska M, Krajewski S, Banares S, Cui J, Digicaylioglu M, Ke N, et al: BI-1 regulates an apoptosis pathway linked to endoplasmic reticulum stress. Mol Cell 15: 355-366, 2004.
28. Ludke AR, Sharma AK, Akolkar G, Bajpai G and Singal PK: Downregulation of vitamin C transporter SVCT-2 in doxorubicin-induced cardiomyocyte injury. Am J Physiol Cell Physiol 303: C645-C653, 2012.
29. Jiang M, Wang CY, Huang S, Yang T and Dong Z: Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway. Am J Physiol Renal Physiol 296: F983-F993, 2009.
30. Salvioli S, Ardizzoni A, Franceschi C and Cossarizza A: JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: Implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 411: 77-82, 1997.
31. Kooy NW, Royall JA, Ischiropoulos H and Beckman JS: Peroxynitrite-mediated oxidation of dihydrorhodamine 123. Free Radic Biol Med 16: 149-156, 1994.
32. Tarpey MM and Fridovich I: Methods of detection of vascular reactive species: Nitric oxide, superoxide, hydrogen peroxide, and peroxynitrite. Circ Res 89: 224-236, 2001.
33. Sobreira C, Davidson M, King MP and Miranda AF: Dihydrorhodamine 123 identifies impaired mitochondrial respiratory chain function in cultured cells harboring mitochondrial DNA mutations. J Histochem Cytochem 44: 571-579, 1996.
34. Crow JP: Dichlorodihydrofluorescein and dihydrorhodamine 123 are sensitive indicators of peroxynitrite in vitro: Implications for intracellular measurement of reactive nitrogen and oxygen species. Nitric Oxide 1: 145-157, 1997.
35. Robinson KM, Janes MS and Beckman JS: The selective detection of mitochondrial superoxide by live cell imaging. Nat Protoc 3: 941-947, 2008.
36. Mukhopadhyay P, Rajesh M, Yoshihiro K, Haskó G and Pacher P: Simple quantitative detection of mitochondrial superoxide production in live cells. Biochem Biophys Res Commun 358: 203-208, 2007.
37. Ito T, Okumura H, Tsukue N, Kobayashi T, Honda K and Sekizawa K: Effect of diesel exhaust particles on mRNA expression of viral and bacterial receptors in rat lung epithelial L2 cells. Toxicol Lett 165: 66-70, 2006.
38. Ly JD, Grubb DR and Lawen A: The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis 8: 115-128, 2003.
39. Tsang WP, Chau SP, Kong SK, Fung KP and Kwok TT: Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 73: 2047-2058, 2003.
40. Sawyer DB, Fukazawa R, Arstall MA and Kelly RA: Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 84: 257-265, 1999.
41. Kotamraju S, Konorev EA, Joseph J and Kalyanaraman B: Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 275: 33585-33592, 2000.
42. Mihm MJ, Yu F, Weinstein DM, Reiser PJ and Bauer JA: Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: Evidence for selective impairment of myofibrillar creatine kinase. Br J Pharmacol 135: 581-588, 2002.
43. Luanpitpong S, Chanvorachote P, Nimmannit U, Leonard SS, Stehlik C, Wang L and Rojanasakul Y: Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination. Biochem Pharmacol 83: 1643-1654, 2012.
44. Lee YJ, Jeong HY, Kim YB, Lee YJ, Won SY, Shim JH, Cho MK, Nam HS and Lee SH: Reactive oxygen species and PI3K/Akt signaling play key roles in the induction of Nrf2-driven heme oxygenase-1 expression in sulforaphane-treated human mesothelioma MSTO-211H cells. Food Chem Toxicol 50: 116-123, 2012.
45. Surh YJ, Na HK and Lee SS: Transcription factors and mitogen-activated protein kinases as molecular targets for chemoprevention with anti-inflammatory phytochemicals. Biofactors 21: 103-108, 2004.
46. Scott JM, Khakoo A, Mackey JR, Haykowsky MJ, Douglas PS and Jones LW: Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: Current evidence and underlying mechanisms. Circulation 124: 642-650, 2011.
47. Kimes BW and Brandt BL: Properties of a clonal muscle cell line from rat heart. Exp Cell Res 98: 367-381, 1976.
48. Watkins SJ, Borthwick GM and Arthur HM: The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell Dev Biol Anim 47: 125-131, 2011.
49. Prathapan A, Vineetha VP, Abhilash PA and Raghu KG: Boerhaavia diffusa L. attenuates angiotensin II-induced hypertrophy in H9c2 cardiac myoblast cells via modulating oxidative stress and down-regulating NF-êB and transforming growth factor β1. Br J Nutr 110: 1201-1210, 2013.
50. Karagiannis TC, Lin AJ, Ververis K, Chang L, Tang MM, Okabe J and El-Osta A: Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging (Albany NY) 2: 659-668, 2010.
51. Merten KE, Jiang Y, Feng W and Kang YJ: Calcineurin activation is not necessary for Doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: Involvement of the phosphoinositide 3-kinase-Akt pathway. J Pharmacol Exp Ther 319: 934-940, 2006.
52. Wang GW, Klein JB and Kang YJ: Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J Pharmacol Exp Ther 298: 461-468, 2001.
53. Hare JM: Oxidative stress and apoptosis in heart failure progression. Circ Res 89: 198-200, 2001.
54. Gao X and Talalay P: Induction of phase 2 genes by sulforaphane protects retinal pigment epithelial cells against photooxidative damage. Proc Natl Acad Sci USA 101: 10446-10451, 2004.
55. Al-Abd AM, Al-Abbasi FA, Asaad GF and Abdel-Naim AB: Didox potentiates the cytotoxic profile of doxorubicin and protects from its cardiotoxicity. Eur J Pharmacol 718: 361-369, 2013.
56. Jay SM, Murthy AC, Hawkins JF, Wortzel JR, Steinhauser ML, Alvarez LM, Gannon J, Macrae CA, Griffith LG and Lee RT: An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential. Circulation 128: 152-161, 2013.
57. Osman AM, Al-Harthi SE, AlArabi OM, Elshal MF, Ramadan WS, Alaama MN, Al-Kreathy HM, Damanhouri ZA and Osman OH: Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell Int 13: 52, 2013.
58. Ahmed LA and El-Maraghy SA: Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: Possible mechanism of cardioprotection. Biochem Pharmacol 86: 1301-1310, 2013.
59. Choi HJ, Seon MR, Lim SS, Kim JS, Chun HS and Park JH: Hexane/ethanol extract of Glycyrrhiza uralensis licorice suppresses doxorubicin-induced apoptosis in H9c2 rat cardiac myoblasts. Exp Biol Med (Maywood) 233: 1554-1560, 2008.
60. Fimognari C, Nüsse M, Lenzi M, Sciuscio D, Cantelli-Forti G and Hrelia P: Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations. Mutat Res 601: 92-101, 2006.
61. Hu L, Miao W, Loignon M, Kandouz M and Batist G: Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. Cancer Chemother Pharmacol 66: 467-474, 2010.